Physician profile
Timothy P Hecker
NPI 1770790628
$23,617.25
in general payments reported to CMS, 2019-2025
69 companies · $4,065 in 2025
The $4,065 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,399 · 2020: $2,473 · 2021: $3,714 · 2022: $3,727 · 2023: $3,173 · 2024: $4,066 · 2025: $4,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $14.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,289.97 |
| Education | $14.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,378.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,274.56 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $1,319.74 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $1,287.71 | 2020-2025 | |
| Biogen, INC. | $1,154.36 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $1,080.38 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Eisai INC. | $1,049.01 | 2019-2025 | |
| Lundbeck LLC | $881.36 | 2020-2025 | Vyepti, Rexulti |
| Celgene Corporation | $875.41 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $851.08 | 2019-2025 | Ultomiris, Koselugo |
| Genzyme Corporation | $755.17 | 2019-2025 | |
| Amgen INC. | $738.68 | 2019-2025 | Uplizna, Aimovig |
| Emd Serono, INC. | $694.83 | 2019-2025 | Mavenclad |
| Pfizer INC. | $655.11 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $609.36 | 2019-2025 | Austedo Xr, Austedo Xr |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $374.49 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Mallinckrodt Hospital Products INC. | $341.67 | 2020-2025 | Acthar |
| Neurocrine Biosciences, INC. | $317.48 | 2019-2025 | Ingrezza, Ongentys |
| Impel Pharmaceuticals INC. | $297.97 | 2022-2023 | Trudhesa |
| Kyowa Kirin, INC. | $297.84 | 2019-2022 | |
| Argenx US, INC. | $266.58 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $263.49 | 2019-2024 | Apokyn |
| Grifols USA, LLC | $254.94 | 2019-2025 | Gamunex-C |
| Biohaven Pharmaceutical Holding Company LTD. | $221.11 | 2022 | |
| Allergan, INC. | $213.11 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $207.47 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $191.75 | 2019-2025 | Dysport |
| Acorda Therapeutics, INC | $184.34 | 2021-2023 | Inbrija |
| Tanabe Pharma America, INC. | $174.18 | 2019-2025 | Radicava |
| Tg Therapeutics, INC. | $164.67 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $144.97 | 2022-2024 | Amvuttra |
| Genentech USA, INC. | $130.60 | 2019-2025 | Ocrevus Zunovo |
| Adamas Pharmaceuticals, INC. | $112.96 | 2020 | |
| Arbor Pharmaceuticals, INC. | $107.70 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $103.11 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $101.90 | 2020-2022 | |
| Catalyst Pharmaceuticals, INC. | $94.15 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $87.98 | 2020-2023 | Ponvory |
| Horizon Therapeutics Plc | $85.64 | 2022-2023 | Uplizna |
| Janssen Biotech, INC. | $83.38 | 2025 | Tremfya |
| Amneal Pharmaceuticals LLC | $80.85 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $77.85 | 2023 | Purified Cortrophin Gel |
| Medtronic, INC. | $75.19 | 2021-2024 | Activa PC, Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $73.53 | 2023-2025 | Rexulti |
| Boston Scientific Corporation | $70.45 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $70.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.58 | 2023-2025 | Hyqvia, Gammagard |
| Averitas Pharma INC. | $62.69 | 2023-2025 | Qutenza |
| Axsome Therapeutics, INC. | $52.86 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $49.17 | 2022-2023 | |
| Merz Pharmaceuticals, LLC | $46.74 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Neurelis, INC. | $46.07 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $37.83 | 2022-2025 | |
| Avion Pharmaceuticals | $35.38 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.33 | 2022-2023 | Quviviq |
| Harmony Biosciences LLC | $33.16 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $32.65 | 2021 | |
| Abbott Laboratories | $31.71 | 2023 | Infinity |
| Sandoz INC. | $30.68 | 2024 | |
| Assertio Therapeutics, INC. | $28.90 | 2020 | |
| Life Molecular Imaging LTD | $25.20 | 2024 | Neuraceq |
| Octapharma USA, INC. | $24.49 | 2024 | Panzyga |
| Csl Behring | $23.92 | 2019 | |
| Silk Road Medical, INC. | $18.04 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Endo Pharmaceuticals INC. | $14.89 | 2019 | |
| Currax Pharmaceuticals LLC | $14.25 | 2020 | |
| Greenwich Biosciences, INC. | $12.57 | 2020 | |
| Akcea Therapeutics, INC. | $10.89 | 2019 | |
| Promius Pharma LLC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.